Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

CTech 24/7

RedHill

4 stories about RedHill

RedHill Receives FDA Approval for H. Pylori Gastric Drug
05.11.19|Tzally GreenbergH. pylori is a type of drug-resistant gastric bacteria linked with increased risks of developing ulcers and stomach cancer
Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection
04.12.18|CTechRedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care
RedHill’s Clinical Trial Results Undermine Its Underwritten Offering
12.08.18|Dror ReichThe gastro treatment company announced a successful Crohn's disease treatment trial two weeks ago. While investors initially seemed hyped, successful trials from competitors brought RedHill’s stock down since
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
24.07.18|Lilach BaumerThe Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market

Twitter

Facebook

Rss

About CTech Terms of Use Privacy Policy

CTech 24/7

RedHill

RedHill Receives FDA Approval for H. Pylori Gastric Drug

Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection

RedHill’s Clinical Trial Results Undermine Its Underwritten Offering

Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq